Clinical cancer research : an official journal of the American Association for Cancer Research
Pembrolizumab and Paclitaxel in HR+/HER2- Breast Cancer with HER2-Enriched or Basal-Like Subtypes.
Benedetta Conte, Fara Brasó-Maristany, Tomás Pascual, Cristina Hernando, Silvia Vázquez, Salvador Blanch, Mafalda Oliveira, Juan Antonio Virizuela, Montserrat Muñoz, Elia Seguí, Adela Rodriguez Hernández, Maria Jesus Vidal Losada, Patricia Galván, Oleguer Castillo, Paula Blasco
Published: 202610.1158/1078-0432.CCR-25-2570
Abstract
PURPOSE: Hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (mBC) is biologically distinct from early-stage disease, with a higher prevalence of genomically defined non-luminal subtypes, particularly the HER2-enriched (HER2…
Preview only. Read the full abstract at the source